Menten AI Stock

Menten AI utilizes machine learning and quantum computing to design proteins for therapeutic and industrial purposes.

Sign up today and learn more about Menten AI Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Menten AI Stock

Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.

Funding History

June 2020$4.0M


Co-Founder and CEO

Hans Melo

Co-Founder and CSO

Tamas Gorbe


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: